

Supplementary Information

Yann Waltenspühl^{1,2}, Janosch Ehrenmann^{1,3,#}, Santiago Vacca^{1,#}, Cristian Thom^{1,#}, Ohad Medalia¹ and Andreas Plückthun^{1*}


¹ *Department of Biochemistry, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland.*

² *Present address: Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv, Denmark*

³ *Present address: leadXpro AG, PARK innovAARE, CH-5234 Villigen, Switzerland*

#These authors contributed equally: Janosch Ehrenmann, Santiago Vacca, Cristian Thom


**Correspondence and requests for materials should be addressed to A.P. (plueckthun@bioc.uzh.ch)*



Supplementary Fig. 1 Purification of OTR_{EM} & complex formation.


a Small-scale analytical size-exclusion chromatography (SEC) profiles from initial purifications of wtOTR (black curve) and OTR-D153Y termed OTR_{EM} (red curve). SEC profiles present fair loads. **b** Agonist profiles of wtOTR and OTR_{EM}. Dose-response curves were obtained from IP1 accumulation assays, and saturation binding assays were measured by whole-cell ligand binding assays. Saturation binding curves are shown with mean \pm standard deviation from six (wtOTR) or three (OTR_{EM}) independent experiments performed in triplicates. IP1 dose response curves are shown with mean \pm standard deviation from six (wtOTR) or two (OTR_{EM}) independent experiments performed in duplicates. Source data are

provided as a Source Data file. **c** SEC profile of the OTR:OT:G_{o/q}:scFv16 complex. The red rectangle highlights the pooled fraction used for cryo-EM analysis. **d** LDS-PAGE gel of the pooled complex fraction and the single components.




Supplementary Fig. 2 Overview of single-particle cryo-EM data processing.

a A representative cryo-EM micrograph of the 11,667 movie stacks of the OTR:OT:Go/q:scFv16 complex. Scale bar, 20 nm. **b** Representative 2D averages showing distinct secondary structure features from different views of the complex. **c** 3D classification workflow and refinement.




Supplementary Fig. 3 Resolution of the OTR:OT:G_{o/q}:scFv16 complex.

a Local resolution analysis of the OTR:OT:G_{o/q}:scFv16 complex. **b** Angular distribution of the particle orientations of the OTR:OT:G_{o/q}:scFv16 complex. **c** The gold-standard Fourier shell correlation curves for the map of the OTR:OT:G_{o/q}:scFv16 complex. **d** For cross-validation, FSC curves of the refined model versus full map (black), refined map versus half map 1 (blue), and refined model versus half map 2 (orange) were calculated.




Supplementary Fig. 4 Cryo-EM density within OTR.

Cryo-EM density maps for all OTR transmembrane helices, helix VIII, oxytocin, and the interacting G_q α5 helix of the G protein.



Supplementary Fig. 5 Conserved activation mechanism by oxytocin and vasopressin.

a Cylindrical representation of active OTR:OT complex with close-up on kink in helix VII. **b** Cylindrical representation of active V₂R:AVP complex (PDB ID: 7DW9 [https://www.rcsb.org/structure/7DW9]) with close-up on kink in helix VII. **c** Amino acid sequence alignment of the kink region for all human oxytocin and vasopressin receptors. Amino acid positions are denoted in Ballesteros-Weinstein numbering (B.-W.). **d** OT affinity profiles of OTR and V_{1A}R kink region mutants. Bars represent differences in affinity of the cognate ligand (mean $pK_D \pm SEM$ from three independent experiments in triplicates) compared to wtOTR or wtV_{1A}R. Source data are provided as a Source Data file. **e** OT IP1 accumulation dose-response curves of OTR and V_{1A}R kink region mutants. Bars represent differences in IP1 accumulation potency of the cognate ligand (mean $pEC_{50} \pm SEM$ from three (OTR A318G) or six (V_{1A}R G337A) independent transfections in duplicates) compared to wtOTR or wtV_{1A}R. Source data are provided as a Source Data file.



Supplementary Fig. 6 Comparison of the OTR and V₂R.

Structural superposition of the OTR:OT with V₂R:AVP (PDB ID: 7QVM [<https://www.rcsb.org/structure/7DW9>]), illustrating the main differences between active OTR and V₂R. Arrows indicate the main differences in helix positioning and length.

Supplementary Table 1 Single-particle cryo-EM statistics.

| | |
|---|-----------------|
| OTR:OT:G _o /q:scFv16 | |
| PDB ID: 7QVM | |
| Data collection | |
| Microscope | Titan Krios G3i |
| Detector | Gatan K3 |
| Energy filter slit width (eV) | 20 |
| Magnification | 130,000 |
| Voltage (kV) | 300 |
| Electron exposure (e ⁻ /Å ²) | 63.7 |
| Defocus range (μm) | 0.8-2.4 |
| Pixel size (Å) | 0.65 |
| Symmetry imposed | C1 |
| Number of Micrographs | 11,667 |
| Initial particle images (no.) | 6.5 Mio |
| Final particle images (no.) | 392,369 |
| Map resolution (Å) | 3.25 |
| FSC threshold | 0.143 |
| Refinement | |
| Number of atoms | |
| All | 8,551 |
| Protein | 8,482 |
| Ligand | 69 |
| Model validation | |
| CC map vs. model (%) | 76 |
| RMSD | |
| Bond lengths (Å) | 0.27 |
| Bond angles (°) | 0.640 |
| Ramachandran statistics | |
| Favored regions (%) | 96.4 |
| Allowed regions (%) | 3.5 |
| Outliers (%) | 0.0 |
| Rotamer outliers (%) | 0.0 |
| C-beta deviations (%) | 0.0 |
| Clashscore | 11.4 |
| <i>MolProbity</i> overall score | 1.8 |

Supplementary Table 2 Effects of mutations on OT-induced IP1-accumulation.

| construct | EC₅₀ [nM] | ΔpEC₅₀ | E_{max} (% of wt) | n |
|---------------------|-----------------------------|--------------------------|----------------------------------|----------|
| wtOTR | 8.4 ± 4 | - | 100 | 6 |
| OTR _{EM} | 42.9 ± 17 | -0.52 ± 0.18 | 229 ± 29 | 2 |
| Q92A | 222.3 ± 141 | -1.72 ± 0.28 | 12 ± 1 | 3 |
| Q96A | 1540 ± 286.3 | -2.75 ± 0.05 | 68 ± 13 | 3 |
| K116A | 6.1 ± 0.8 | -0.36 ± 0.03 | 48 ± 5 | 3 |
| Q119A | 444.3 ± 192.6 | -2.15 ± 0.16 | 107 ± 33 | 3 |
| M123A | n.a. | - | (1 ± 1) | 3 |
| Q171A | 992.5 ± 180 | -2.56 ± 0.04 | 90 ± 12 | 3 |
| Q171N | 39.1 ± 10.2 | -1.14 ± 0.1 | 74 ± 11 | 3 |
| F175A | 3482 ± 857.7 | -3.09 ± 0.07 | 66 ± 12 | 3 |
| W188A | 155.7 ± 62 | -1.08 ± 0.18 | 85 ± 9 | 2 |
| I201A | 89.5 ± 15.4 | -1.52 ± 0.12 | 22 ± 7 | 3 |
| I204A | n.a. | - | (-2 ± 4) | 3 |
| F291A | 541.8 ± 179.4 | -1.63 ± 0.51 | 28 ± 7 | 2 |
| F292A | 6.1 ± 3.3 | 0.36 ± 0.62 | 9 ± 1 | 2 |
| Q295A | 51.3 ± 3.1 | -0.63 ± 0.34 | 32 ± 1 | 2 |
| L316A | 21.9 ± 10.7 | -0.21 ± 0.13 | 18 ± 4 | 2 |
| A318G | 4.6 ± 0.7 | 0.39 ± 0.2 | 50 ± 2 | 3 |
| wtV _{1A} R | 157.8 ± 27.6 | - | 100 | 6 |
| G337A | 249.7 ± 90.5 | -0.14 ± 0.06 | 215 ± 15 | 6 |

HTRF-based measurements of IP1 accumulation in HEK293T cells expressing wild-type and mutated receptor variants. Activation curves were analyzed by fitting each experiment separately to a three-parameter logistic equation. All values are expressed as mean ± SEM of the indicated number of independent experiments performed in duplicate. n.a., no activation. Source data are provided as a Source Data file.

Supplementary Table 3 Effects of mutations on OT binding.

| construct | K_D [nM] | ΔpK_D | B_{max} (% of wt) | n |
|---------------------|---------------------------|------------------------|----------------------------------|----------|
| wtOTR | 1.4 ± 0.2 | 0 | 100 | 6 |
| OTR _{EM} | 6.4 ± 0.7 | -0.6 ± 0.1 | 252 ± 10 | 3 |
| A318G | 0.9 ± 0.2 | 0.28 ± 0.17 | 28 ± 5 | 3 |
| wtV _{1A} R | 9.3 ± 2.2 | 0 | 100 | 3 |
| G337A | 20.9 ± 0.2 | -0.38 ± 0.11 | 165 ± 23 | 3 |

Whole-cell specific saturation binding experiment of fluorescently labelled peptide OT-HL488 to HEK293T cells expressing wild-type and mutated receptor variants. Binding curves were analyzed by fitting each experiment separately to a one-site saturation binding equation. All values are expressed as mean ± SEM of the indicated number of independent experiments performed in triplicate. B_{max} values indicate the amount of functional receptor. Source data are provided as a Source Data file.